Ability Biologics Innovates AI-Driven Antibody Therapeutics with $18 Million Seed Funding Boost
Ability Biologics, a trailblazer in AI-driven therapeutic discovery, has closed an $18 million seed funding extension, marking a significant milestone in its quest to revolutionize antibody therapeutics for cancer and immune-related disorders. Led by founding investor Amplitude Ventures, this financing round includes strategic support from Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus,…